Company Description
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States.
The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.
It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer.
ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation.
The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Dr. Uttam Yashwant Patil Ph.D. |
Contact Details
Address: 44370 Old Warm Springs Blvd. Fremont, California 94538 United States | |
| Phone | 510-668-0881 |
| Website | abvcpharma.com |
Stock Details
| Ticker Symbol | ABVC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001173313 |
| CUSIP Number | 00091F106 |
| ISIN Number | US00091F3047 |
| Employer ID | 26-0014658 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Eugene Jiang | Chairman and Chief Business Officer |
| Dr. Uttam Yashwant Patil Ph.D. | Chief Executive Officer |
| Leeds Chow | Chief Financial Officer and Principal Accounting Officer |
| Dr. Tsung-Shann Jiang EMBA, Ph.D. | Chief Scientific Officer, Chief Strategy Officer and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 19, 2024 | 8-K | Current Report |
| Apr 17, 2024 | 8-K | Current Report |
| Apr 5, 2024 | 424B4 | Prospectus |
| Apr 1, 2024 | EFFECT | Notice of Effectiveness |
| Mar 26, 2024 | 8-K | Current Report |
| Mar 25, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 22, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Mar 15, 2024 | 10-K/A | [Amend] Annual report |
| Mar 14, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 14, 2024 | 8-K | Current Report |